CCIA
ELOS

Campbell & Co Investment Adviser’s Syneron Medical Ltd ELOS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-22,781
Closed -$240K – 396
2017
Q1 		$240K Buy
22,781
+5,065
+29% +$49K 0.62% 79
2016
Q4 		$149K Buy
17,716
+7,468
+73% +$58.5K 0.46% 105
2016
Q3 		$73K Buy
+10,248
New +$71.3K 0.2% 138

Other funds holding ELOS

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Campbell & Co Investment Adviser's ELOS Position: Q2 2017 in Review

Campbell & Co Investment Adviser sold out of Syneron Medical Ltd (ELOS) in Q2 2017, closing a stake of 22,781 shares — an estimated $240K sold.

Campbell & Co Investment Adviser first reported a position in ELOS in Q3 2016 and held it in 3 quarters. The position peaked at $240K in Q1 2017. 79 funds tracked by Wall St. Rank hold ELOS as of Q2 2017.

  • Campbell & Co Investment Adviser reported no remaining Syneron Medical Ltd position as of Q2 2017 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 22,781 Syneron Medical Ltd shares in Q2 2017, an estimated $240K.
  • Campbell & Co Investment Adviser first reported a position in Syneron Medical Ltd in Q3 2016 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Syneron Medical Ltd position peaked at $240K in Q1 2017.
  • 79 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q2 2017.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2017, filed 26 Jul 2017.